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Abstract We compared the effects of two anti-ßl integrin 
activating antibodies, TS2/16 and AG89, on K562 cell adhesion 
to fibronectin. Though both antibodies effectively induced cell 
adhesion, the EC50 for AG89 was more than 200-fold higher than 
that for TS2/16. Scatchard analysis of the data from I125I]Fab 
fragment binding to the cells revealed that the TS2/16 epitope is 
exposed constitutively on all the ßl integrin molecules, while only 
3% of the ßl integrins on resting K562 cells bear the AG89 
epitope. Calculation of the actual number of each antibody bound 
to the cell during the cell adhesion assay revealed that induction 
of cell adhesion can be accomplished by binding much fewer 
AG89 molecules compared to TS2/16. Thus, AG89 and TS2/16 
represent distinct classes of anti-integrin activating antibodies 
that show completely different binding characteristics as well as 
different activation effects on the integrin molecule upon binding. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Integrins are heterodimeric transmembrane proteins con-
sisting of a and ß subunits and mediate cell adhesion to ex-
tracellular matrix proteins as well as cell-cell interactions [1-
3]. Integrin-mediated cell adhesion plays crucial roles in reg-
ulating the morphology, proliferation, migration and differ-
entiation of cells. It is widely accepted that availability of 
integrins as adhesion receptors is dynamically regulated 
[4,5]. For example, integrins on floating cells such as leuko-
cytes and platelets are usually inactive; they need to be 'acti-
vated' by various stimuli prior to displaying the binding to 
their extracellular ligands [6-8]. Such activating stimuli in-
clude activation of protein kinase C [9], cross-linking of sev-
eral cell surface receptors [6,10], and binding of agonist to G 
protein-coupled receptors [8,11,12]. In addition, several 'acti-
vating antibodies' to integrin itself have been reported. These 
antibodies, most of them directed against ß chains, are 
thought to cause conformational change in integrin molecules 
that results in conversion of resting integrins to active ones. 
TS2/16 is a well-known anti-ßl activating monoclonal anti-
body (niAb) which recognizes an epitope in the putative li-
gand binding region [13]. This mAb can promote various ßl 
integrin-mediated cell adhesions at concentrations as low as 
0.1 |xg/ml. Recently, we have established an anti-ßl integrin 
mAb AG89 which also has adhesion-promoting activity [14]. 
It recognizes an epitope in the membrane proximal stalk-like 
region of ßl integrin, which is distant from the epitope for 
TS2/16. It was revealed that AG89 fell into a group of anti-
bodies called anti-ligand induced binding site (or LIBS) anti-
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body since binding of AG89 to cells is increased upon ligation 
of integrins. Most of the anti-LIBS mAbs against integrin ß 
chains are reported to have adhesion-promoting activity, like 
AG89 [15-20]. In most cases, however, it has also been re-
ported that high concentrations of these mAbs are required to 
achieve their activating effect. In order to get some insight 
into the difference between the activating effects of activating 
mAbs, we investigated the binding characteristics of TS2/16 
and AG89 to K562 cells. By employing Scatchard analysis, it 
was revealed that only a limited number of ßl integrins on 
resting K562 cells bear the AG89 epitope while TS2/16 can 
bind to all the ßl integrins on the resting cells. Comparison of 
the binding data with the adhesion-promoting activity of these 
antibodies suggests that TS2/16 and AG89 can be distin-
guished as different classes of antibodies that activate ßl in-
tegrin. 
2. Materials and methods 
2.1. Materials 
The preparation of activating antibody against human ßl integrin, 
AG89, has been described [14]. The hybridoma cell line secreting 
another anti-ßl activating antibody, TS2/16 [21], was obtained from 
the ATCC (#HB243). Both antibodies were obtained in ascites, and 
purified by ammonium sulfate precipitation and anion-exchange chro-
matography. Fab as well as F(ab')2 fragments of these antibodies 
were prepared using immobilized papain or pepsin (Pierce Chemical 
Co., Rockford, IL) followed by purification by a protein A-agarose. 
The absence of undigested IgG was confirmed by SDS-PAGE under 
non-reducing conditions. The function blocking antibody against 
FcyRII (IV.3) was purchased from Medarex Inc. (West Lebanon, 
NH). Bovine plasma fibronectin was purified as described previously 
[22]. 
2.2. Cell adhesion assay 
The human erythroleukemic cell line K562 was provided by the 
Japanese Cancer Research Resources Bank (Tokyo, Japan) and cul-
tured in RPMI 1640 medium containing 10% fetal calf serum and 
non-essential amino acids. The cell adhesion assay was carried out 
by a method essentially described previously [23]. In brief, wells of 
96-well microtiter plates were coated with 3 |xg/ml bovine plasma 
fibronectin in PBS and incubated at 4°C overnight and non-specific 
binding sites were blocked by incubation with 1% bovine serum albu-
min for 30 min at room temperature. K562 cells (105 cells/well) in 100 
|il of serum-free RPMI 1640 were added to the wells and incubated 
for 1 h at 37°C in the presence or absence of varying concentrations of 
mAbs. After removing the unbound cells by rinsing the wells three 
times with PBS, the bound cells were quantified by incubation with 
100 |xl of the phosphatase assay buffer (50 mM sodium acetate, 1% 
Triton X-100, 6 mg/ml p-nitrophenylphosphate, pH 5.2) for 1 h fol-
lowed by addition of 50 ul of 1 N NaOH and measurement of ab-
sorbance at 405 nm. 
2.3. Fab binding assay 
The Fab fragments were labeled with 125I using Iodo-Beads (Pierce) 
according to the method described previously [24]. Iodinated proteins 
were separated from free 125I by gel filtration on desalting column 
DG-10 (Bio-Rad) equilibrated with 5 mM HEPES, 138 mM NaCl, 
2.9 mM KC1, 12 mM NaHCOs, 5.5 mM glucose, pH 7.2 (HEPES-
Tyrode's buffer; HT). The specific activity of the radiolabeled Fab 
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Fig. 1. Effect of activating mAbs on the K562 cell adhesion to fi-
bronectin. K562 cells suspended in serum-free RPMI 1640 medium 
were treated with increasing concentrations of TS2/16 IgG (•) , TS2/ 
16 Fab (o), AG89 IgG (A) , or AG89 Fab (A) for 30 min and 
added to the wells that had been coated with 3 ug/ml bovine plasma 
fibronectin. After 1 h incubation at 37°C, unbound cells were re-
moved by washing and bound cells were quantitated using the phos-
phatase assay. Data are from a representative experiment in which 
triplicate determinations were made and are expressed as mean± 
S.E.M. 
fragments was in the range of 400-725 MBq/mg protein. Aliquots 
were stored at 4°C after the addition of BSA to a final concentration 
of 1%. K562 cells were washed once with HT and incubated with 
5 mM EDTA at 37°C for 20 min in order to remove cell-bound 
divalent cations as well as fibronectin originating from the culture 
medium. After that, cells were washed three times, suspended in HT 
containing 1 mg/ml BSA, 0.42 mM CaCl2, 0.2 mM MgCl2 (the same 
divalent cation composition as that of RPMI 1640 medium) and mixed 
with the same buffer containing varying concentrations of [125I]Fab 
fragments in a U-bottom microtiter well (Falcon #3910). The typical 
reaction mixture comprised 25 ill of cells (6X 105 per tube), 25 ¡J.1 of 
radiolabeled protein, and 10 ul of reagents (e.g. unlabeled Fab, diva-
lent cations, EDTA, RGD peptide, etc.). The mixtures were incubated 
at 37°C with occasional agitation for 40 min, under which condition 
the binding of both Fab fragments reached plateau. After the incu-
bation, 50-ul aliquots were layered onto 400 |xl of 20% sucrose in the 
same buffer in microfuge tubes, and the cells were separated from 
unbound Fab by centrifugation for 4 min at 12000 rpm. The tips 
of the tubes were cut and the radioactivity associated with the cell 
pellet was counted in a well-type y-counter. Non-specific binding was 
determined in the presence of a 100-fold excess of cold Fab fragment. 
The data were subjected to Scatchard analysis using RADLIG soft-
ware version 4.0 (Biosoft, Cambridge, UK). 
3. Results 
The human erythroleukemic cell line K562 expresses only 
c o ß l as ßl class of integrin on the surface, and K562 cell 
adhesion to fibronectin is exclusively mediated by cc5ßl, which 
was confirmed by complete inhibition by function blocking 
ant i -a5 m A b (data not shown). When coated at a relatively 
low concentration (3 ug/ml), fibronectin cannot promote the 
adhesion of K562 cells unless the cells are treated with some 
activating agent such as activating mAbs and M n 2 + ion [14]. 
As clearly shown in Fig. 1, TS2/16 and AG89 induced K562 
cell adhesion to fibronectin in a dose-dependent manner. 
However, there are two clear differences between the activat-
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Fig. 2. Effect of anti-FcyRII antibody on the activating ability of 
AG89. K562 cells were preincubated in the absence (closed columns) 
or presence (open columns) of 2 ug/ml anti-FcyRII mAb IV.3 for 
30 min and subjected to the cell adhesion assay in the presence of 
either AG89 IgG (A) or its Fab fragments (B) as in Fig. 1. Note 
that the increased activating effect of AG89 IgG compared to the 
Fab fragment was diminished upon treatment with anti-FcyRII 
function-neutralizing mAb IV.3. 
ing effect of these antibodies. First, AG89 IgG showed in-
creased adhesion-promoting activity compared with its F a b 
fragment at concentrations between 0.8 and 30 n M , while 
the dose-response curves of TS2/16 F a b and IgG are identical. 
Second, much higher concentrations were required for both 
the IgG and Fab portions of AG89 to promote adhesion than 
for TS2/16. 
The first difference seems to be due to the involvement of 
the Fc port ion of AG89 IgG in the activation step, since the 
dose-response curve for the F(ab ' )2 fragment of AG89 was 
almost identical to that of the F a b fragment (data not shown). 
As it is well known that K562 cells express FcyRII (CD32) on 
their surface, we looked into the effect of anti-FcyRII anti-
body on mAb-induced cell adhesion. As shown in Fig. 2A, 
prior treatment of the cells with an anti-FcyRII antibody 
(IV.3) abolished the activating effect of 8 n M AG89 IgG 
but had no effect on the maximum adhesion induced by 800 
n M AG89. Moreover, neither an inhibiting nor an enhancing 
effect of IV.3 was observed with cell adhesion induced by 
AG89 Fab (Fig. 2B). It is concluded that the increased acti-
vating effect of IgG relative to the F a b fragment is attribut-
able to the increased binding of AG89 via interaction of the 
Fc port ion of AG89 and Fc receptors (FcyRII) on K562 cells. 
As the EC 5 0 of TS2/16 and AG89 F a b for promoting K562 
adhesion estimated from multiple experiments shown in Fig. 1 
are ~ 0 . 3 n M and ~ 6 0 nM, respectively (Table 1), affinities 
of these mAbs seem to differ by more than two orders of 
magnitude. We then analyzed binding of the 125I-labeled 
Fab fragments of each m A b to K562 cells. As shown in 
Fig. 3, both mAbs showed specific and saturable binding to 
resting K562 cells. Scatchard analyses of the binding da ta 
suggest that each m A b has a single class of binding sites 
with an apparent dissociation constant (K¿) of 12.7 n M (for 
TS2/16) and 41.5 n M (for AG89), which differ by only 4-fold 
(Table 1). On the other hand, it was revealed that AG89 can 
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Fig. 3. Binding of 125I-labeled Fab fragment of TS2/16 (left panel) 
or AG89 (right panel) to K562 cells. Increasing concentrations of 
125I-labeled Fab fragment of TS2/16 or AG89 were incubated with 
K562 cells in HEPES-Tyrode's buffer at 37°C for 40 min. Unbound 
Fab fragments were separated by centrifugation of the cell suspen-
sion through a 20% sucrose solution and the radioactivity associated 
with cells was counted. Amounts of bound Fab fragments were cal-
culated by the specific activity. Data are from representative experi-
ments in which duplicate determinations were made. Inset, Scatch-
ard analyses of the data were performed using the LIGAND 
program [29]. 
recognize only a limited population of ßl integrin on the 
resting cell surface; the maximum binding site numbers were 
178 000 ±9000 sites/cell for TS2/16 and 5500 ±600 sites/cell 
for AG89. We can calculate the actual number of bound 





where [Fab] is the concentration of Fab fragment added. Ac-
cording to this equation, the numbers of Fab fragments 
bound to the cells during the cell adhesion assay were esti-
mated and data from multiple cell adhesion experiments were 
re-plotted with this parameter. As shown in Fig. 4, plotting 
the extent of cell adhesion induced by TS2/16 versus the num-
ber of TS2/16 molecules bound resulted in a typical sigmoidal 
curve consistent with the situation where the strength of the 
cell adhesion is dependent primarily on the density of acti-
vated ßl integrin on the cells. On the other hand, the situation 
was completely different in the case of AG89. Although the 
threshold numbers of bound Fab molecules required for in-
duction of a low level of adhesion ( < 20%) were almost the 
same for both TS2/16 and AG89, a very small number of 
AG89 Fab binding ( ~ 5000/cells) could induce more than 
90% cell adhesion whereas binding of ~ 50 000 TS2/16 Fab 
molecules is required to induce the same degree of adhesion. 
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Fig. 4. Relationship between numbers of TS2/16 (closed circles) or 
AG89 (open circles) Fab bound to the cells and the extent of cell 
adhesion. Cell adhesion assays were performed as described in the 
legend to Fig. 1 and the numbers of Fab fragment bound were cal-
culated by the equation described in the text. Data are mean± 
S.E.M. from seven (AG89) or four (TS2/16) independent experi-
ments in which duplicate determinations were made. 
This progressive increase in the adhesion-promoting ability of 
AG89 with a small number of bound Fab suggests a differ-
ence between TS2/16 and AG89 in the mechanism of activa-
tion of ßl integrin. 
4. Discussion 
We show here that anti-ßl integrin monoclonal antibody 
AG89, which has rather weak affinity (A!d=41 nM), binds 
and activates only limited numbers of ßl integrin on the sur-
face of resting K562 cells in contrast to TS2/16. AG89 IgG 
could promote cell adhesion to fibronectin at a concentration 
much lower than that required for its Fab fragment (Fig. 1). 
This increased activating ability of IgG is attributable to the 
stabilizing effect of the Fc-FcyRII interactions on AG89-ßl 
integrin association, because pretreatment with a function 
blocking antibody to FcyRII abrogated the cell adhesion in-
duced by a low concentration of AG89 IgG. As addition of 
control IgG at concentrations up to 1 mg/ml by itself did not 
induce K562 cell adhesion, it seems that the activation of the 
integrin by AG89 is exclusively mediated by the binding of the 
antibody to ßl integrin and the existence of the Fc portion 
merely increases the apparent affinity to the cell surface anti-
gen. 
In a previous paper [14], we reported that the ability of 
AG89 to induce FITC-fibronectin binding to cells in suspen-
sion is significantly lower than that of TS2/16. A similar dif-
ference was observed in the cell adhesion assay (Fig. 1). As the 
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EC50 for AG89 to induce cell adhesion was 200-fold higher 
than that for TS2/16, it was anticipated that the affinity of 
AG89 to ßl integrin was 200-fold lower. Upon performing 
Scatchard analysis of the binding data, however, it was re-
vealed that the affinity of the two antibodies differed by 
only 4-fold. On the other hand, the numbers of maximum 
binding sites were quite different, though both antibodies rec-
ognize the integrin ßl chain. The number of binding sites on 
K562 cells for TS2/16 ( ~ 180000 molecules/cell) fits very well 
with the reported number of fibronectin receptors on K562 
cells (199000/cell) [25] indicating that this antibody can bind 
to almost all ßl integrin molecules expressed on the cells. The 
number of biding sites for AG89, on the other hand, was 
much lower ( ~ 6000/cell), accounting for only 3% of the total 
ßl integrin molecules. It is obvious that this limited number of 
binding sites on the resting cells is responsible for the rela-
tively poor effectiveness of AG89 to induce cell adhesion. As 
the addition of the RGD ligand peptide together with divalent 
cations to K562 cells greatly increased the number of AG89 
binding sites leaving the K¿ value unchanged (unpublished 
data), it is concluded that ßl integrin on resting K562 cells 
exists as two distinct classes; only 3% of the ßl integrins bear 
the AG89 epitope constitutively and the rest of the ßl integrin 
pool expose the AG89 epitope only after binding of the li-
gand. In spite of the full expression of the AG89 epitope, 
integrins in this 3% pool seem to be in the low affinity state 
because they cannot mediate cell adhesion until bound by the 
activating mAb (Fig. 1). 
A number of activating m Abs against integrin ßl chain 
have been reported so far. Table 2 summarizes the epitope 
localization of those stimulatory antibodies. It is obvious 
that most of them fall into either of two groups with respect 
to their epitope localization: one recognizes a very short 
stretch of residues (residues 207-218) located in the predicted 
ligand-binding domain, and the other has the epitope in or 
near the cysteine-rich repeats (residues 442-629) located in the 
membrane proximal stalk-like region. It is noteworthy that 
activating mAbs that recognize LIBS on ßl integrin (i.e. 15/ 
7, 9EG7, and AG89) all belong to the latter group. Interest-
ingly, epitopes for a series of anti-ß3 LIBS mAbs are also 
mapped to a similar region in the ß3 chain [18,26] and most 
of these mAbs have a stimulatory effect when added at a high 
concentration. It is likely that these 'conformation-dependent' 
antibodies exert their activating effect by binding to the epit-
ope that is exposed on certain populations of integrin recep-
tors under physiological conditions. Although the extents of 
cell adhesions induced by both TS2/16 and AG89 increase as 
a function of the number of each mAb bound on the cells, the 
effect of AG89 was more pronounced than that of TS2/16 
(Fig. 4). In other words, the increase in cell adhesion induced 
by AG89 was much more sensitive to the small increase in the 
number of bound mAbs than in the case of TS2/16-induced 
adhesion. There are several possible explanations for this phe-
nomenon. (1) The ßl integrins that constitutively express the 
AG89 epitope are qualitatively different from the others and a 
very small number of integrins in this population can effec-
tively mediate cell adhesion upon activation. (2) Two anti-
bodies activate ßl integrin in different ways: the ligand-bind-
ing affinity of the ßl integrin bound by AG89 is higher than 
that bound by TS2/16. (3) Binding of AG89 but not TS2/16 
can transduce certain signals into the cells resulting in 'inside-
out'-type up-regulation of cell adhesion. It is also possible that 
the actual number of AG89 molecules bound to the cells 
during the cell adhesion assay is larger than the estimate 
shown in Fig. 4, because of the progressive expression of 
AG89 epitopes on integrin transiently interacting with immo-
bilized fibronectin. Direct measurement of ligand-binding af-
finity of individual integrin molecules activated by each mAb 
will be necessary to clarify these points. 
Integrin activation is accomplished by various mechanisms, 
but their mode of action is variable. For example, up-regula-
tion of integrin-mediated cell adhesion by phorbol esters is 
exerted by increasing the mobility of the integrin on the cell 
membrane but not by increasing the affinity for ligands [27]. 
In contrast, the adhesion-promoting effect of Mn ion is as-
cribed to the direct binding of Mn ion to the integrin extra-
cellular domain that results in increased ligand-binding affinity 
of individual integrin molecules [28]. Activation antibodies are 
also thought to facilitate cell adhesion by converting low af-
finity integrin molecules to a high affinity state through direct 
binding and induction of conformational changes. The present 
study suggests that activation antibodies can be subdivided 
into distinct classes with regard to their binding characteristics 
and activation mechanisms. Thus TS2/16 and AG89 represent 
two distinct prototypes of activating antibodies: one that 
binds and activates all the ßl integrin molecules and one 
that binds to a small fraction of integrin on the resting cells. 
Molecular determinants that define the differential expression 
of the AG89 epitope on the ßl integrin molecule, as well as 
the physiological importance of the existence of two different 
classes of receptors on resting cells remain to be elucidated. 
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